To include your compound in the COVID-19 Resource Center, submit it here.

Innocoll jumps on Phase III data for analgesic implant

Innocoll AG (NASDAQ:INNL) gained $3.40 (48%) to $10.51 after its XaraColl bupivacaine collagen

Read the full 138 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE